CO7160042A2 - Építopos de antigeno de superficie del receptor de factor de crecimiento epidérmico y uso de los mismos - Google Patents
Építopos de antigeno de superficie del receptor de factor de crecimiento epidérmico y uso de los mismosInfo
- Publication number
- CO7160042A2 CO7160042A2 CO14234763A CO14234763A CO7160042A2 CO 7160042 A2 CO7160042 A2 CO 7160042A2 CO 14234763 A CO14234763 A CO 14234763A CO 14234763 A CO14234763 A CO 14234763A CO 7160042 A2 CO7160042 A2 CO 7160042A2
- Authority
- CO
- Colombia
- Prior art keywords
- egf
- epitopes
- egfr
- growth factor
- epidermal growth
- Prior art date
Links
- 102000001301 EGF receptor Human genes 0.000 title abstract 7
- 108060006698 EGF receptor Proteins 0.000 title abstract 7
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 3
- 101800003838 Epidermal growth factor Proteins 0.000 abstract 3
- 229940116977 epidermal growth factor Drugs 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000018710 Heparin-binding EGF-like Growth Factor Human genes 0.000 abstract 1
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001131—Epidermal growth factor [EGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Virology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261616073P | 2012-03-27 | 2012-03-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO7160042A2 true CO7160042A2 (es) | 2015-01-15 |
Family
ID=49260689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14234763A CO7160042A2 (es) | 2012-03-27 | 2014-10-23 | Építopos de antigeno de superficie del receptor de factor de crecimiento epidérmico y uso de los mismos |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20150231220A1 (enExample) |
| EP (1) | EP2832363B1 (enExample) |
| JP (1) | JP6209206B2 (enExample) |
| KR (1) | KR101930019B1 (enExample) |
| CN (2) | CN104394879A (enExample) |
| BR (1) | BR112014024192A2 (enExample) |
| CA (1) | CA2871111C (enExample) |
| CO (1) | CO7160042A2 (enExample) |
| DK (1) | DK2832363T3 (enExample) |
| ES (1) | ES2694679T3 (enExample) |
| IN (1) | IN2014DN08778A (enExample) |
| MX (1) | MX356550B (enExample) |
| MY (1) | MY168077A (enExample) |
| PH (1) | PH12014502360A1 (enExample) |
| RU (1) | RU2650770C2 (enExample) |
| WO (1) | WO2013147509A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10759836B2 (en) | 2014-07-18 | 2020-09-01 | University Of Washington | Cancer vaccine compositions and methods of use thereof |
| KR101776879B1 (ko) * | 2015-01-19 | 2017-09-08 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
| CN115226700A (zh) * | 2022-08-02 | 2022-10-25 | 江苏克诺克智能科技有限公司 | 一种粮面害虫诱捕器及诱捕系统 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5459061A (en) * | 1990-01-26 | 1995-10-17 | W. Alton Jones Cell Science Center, Inc. | Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US7063943B1 (en) | 1990-07-10 | 2006-06-20 | Cambridge Antibody Technology | Methods for producing members of specific binding pairs |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0975748B1 (en) | 1997-04-23 | 2006-03-29 | Universität Zürich | Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules |
| GB2339430A (en) | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
| US7732157B1 (en) * | 1999-09-30 | 2010-06-08 | Tumor Biology Investment Group | Soluble epidermal growth factor receptor-like proteins and their uses in cancer detection methods |
| ES2259030T3 (es) * | 2000-05-19 | 2006-09-16 | Scancell Limited | Anticuerpos humanizados frente al receptor del factor de crecimiento epidermico. |
| AUPQ841800A0 (en) * | 2000-06-28 | 2000-07-20 | Biomolecular Research Institute Limited | Truncated egf receptor |
| RU2335507C2 (ru) * | 2001-06-13 | 2008-10-10 | Генмаб А/С | Человеческие моноклональные антитела к рецептору эпидермального фактора роста (egfr), способ их получения и их использование, гибридома, трансфектома, трансгенное животное, экспрессионный вектор |
| JP2003066677A (ja) * | 2001-08-24 | 2003-03-05 | Canon Inc | カラー画像形成装置及び画像補正制御方法並びに記憶媒体 |
| EP3037105B1 (en) * | 2003-06-27 | 2021-03-17 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| US7767792B2 (en) * | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| WO2006082515A2 (en) * | 2005-02-07 | 2006-08-10 | Glycart Biotechnology Ag | Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof |
| US20080253993A1 (en) * | 2005-03-31 | 2008-10-16 | Pharmexa A/S | Immunogenic Egfr Peptides Comprising Foreign T Cell Stimulating Epitope |
| US7985559B2 (en) * | 2007-10-19 | 2011-07-26 | Amgen Inc. | Methods of selecting epidermal growth factor receptor (EGFR) binding agents |
| WO2010040209A1 (en) * | 2008-10-06 | 2010-04-15 | The University Of British Columbia | Methods and systems for predicting misfolded protein epitopes |
| KR101108642B1 (ko) | 2009-09-29 | 2012-02-09 | 주식회사 녹십자 | 표피 성장 인자 수용체에 특이적으로 결합하는 항체 |
| US8962808B2 (en) * | 2010-05-05 | 2015-02-24 | The Research Foundation For The State University Of New York | EGFR-related polypeptides and methods of use |
-
2013
- 2013-03-27 CN CN201380022281.4A patent/CN104394879A/zh active Pending
- 2013-03-27 IN IN8778DEN2014 patent/IN2014DN08778A/en unknown
- 2013-03-27 US US14/388,665 patent/US20150231220A1/en not_active Abandoned
- 2013-03-27 MY MYPI2014702810A patent/MY168077A/en unknown
- 2013-03-27 ES ES13769431.1T patent/ES2694679T3/es active Active
- 2013-03-27 WO PCT/KR2013/002550 patent/WO2013147509A1/ko not_active Ceased
- 2013-03-27 KR KR1020147027485A patent/KR101930019B1/ko not_active Expired - Fee Related
- 2013-03-27 BR BR112014024192A patent/BR112014024192A2/pt not_active Application Discontinuation
- 2013-03-27 MX MX2014011597A patent/MX356550B/es active IP Right Grant
- 2013-03-27 DK DK13769431.1T patent/DK2832363T3/en active
- 2013-03-27 JP JP2015503118A patent/JP6209206B2/ja not_active Expired - Fee Related
- 2013-03-27 EP EP13769431.1A patent/EP2832363B1/en active Active
- 2013-03-27 RU RU2014143032A patent/RU2650770C2/ru active
- 2013-03-27 CA CA2871111A patent/CA2871111C/en active Active
- 2013-03-27 CN CN201910572748.1A patent/CN110317259A/zh active Pending
-
2014
- 2014-10-22 PH PH12014502360A patent/PH12014502360A1/en unknown
- 2014-10-23 CO CO14234763A patent/CO7160042A2/es unknown
-
2017
- 2017-02-06 US US15/425,413 patent/US20170145107A1/en not_active Abandoned
-
2019
- 2019-01-28 US US16/259,509 patent/US20190153117A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015519875A (ja) | 2015-07-16 |
| MX356550B (es) | 2018-06-01 |
| US20170145107A1 (en) | 2017-05-25 |
| RU2014143032A (ru) | 2016-05-20 |
| EP2832363B1 (en) | 2018-09-19 |
| MY168077A (en) | 2018-10-11 |
| CA2871111C (en) | 2022-06-28 |
| MX2014011597A (es) | 2015-03-10 |
| CN104394879A (zh) | 2015-03-04 |
| WO2013147509A1 (ko) | 2013-10-03 |
| KR101930019B1 (ko) | 2018-12-17 |
| EP2832363A4 (en) | 2016-03-23 |
| KR20140145583A (ko) | 2014-12-23 |
| PH12014502360B1 (en) | 2015-01-12 |
| US20190153117A1 (en) | 2019-05-23 |
| ES2694679T3 (es) | 2018-12-26 |
| CA2871111A1 (en) | 2013-10-03 |
| BR112014024192A2 (pt) | 2017-07-25 |
| RU2650770C2 (ru) | 2018-04-17 |
| EP2832363A1 (en) | 2015-02-04 |
| IN2014DN08778A (enExample) | 2015-05-22 |
| CN110317259A (zh) | 2019-10-11 |
| DK2832363T3 (en) | 2019-01-07 |
| PH12014502360A1 (en) | 2015-01-12 |
| US20150231220A1 (en) | 2015-08-20 |
| JP6209206B2 (ja) | 2017-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022002448A1 (es) | Constructos de anticuerpo para flt3 y cd3 (divisional sol.: 201800269) | |
| CL2016003040A1 (es) | Moléculas de unión tri-específicas y métodos de uso de las mismas. | |
| CO2018001485A2 (es) | Diacuerpos monovalentes biespecificos que son capaces de unirse a b7 - h3 y cd3 | |
| CY1121392T1 (el) | Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης | |
| MX2016012094A (es) | Composiciones de anticuerpos para tratamiento tumoral. | |
| CO2018010538A2 (es) | Anticuerpos específicos del receptor de poliovirus humano (rvp) | |
| BR112019011450A2 (pt) | células naturais killer modificadas e uso das mesmas | |
| MX362456B (es) | Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis. | |
| CL2015001356A1 (es) | Anticuerpos bioespecificos egfr/c-met | |
| MX2018012076A (es) | Composiciones y anticuerpos anti proteina 3 que contiene inmunoglobulina de linfocitos t y el dominio de mucina (tim-3). | |
| MX2019007554A (es) | Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso. | |
| CO2018000211A2 (es) | Moléculas de anticuerpo que se unen a cd45 | |
| EA201890866A1 (ru) | Связывающие молекулы, которые ингибируют рост рака | |
| JO3788B1 (ar) | تراكيب جسم مضاد لـ egfrviii وcd3 | |
| MX377844B (es) | Anticuerpos anti proteína relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticóides (gitr) y sus métodos de uso. | |
| EA201890655A1 (ru) | Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул | |
| EA201492101A1 (ru) | Антитела против fcrn | |
| EA201390472A1 (ru) | Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты | |
| MX373245B (es) | Anticuerpos cd3 humanizados o quiméricos. | |
| UY36302A (es) | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas | |
| BR112016014731A2 (pt) | Anticorpos anti-baff | |
| MX376324B (es) | Proteinas de union a desmogelina 2 (dsg2) y usos de los mismos. | |
| EA201690992A1 (ru) | Антитела, специфичные к fcrn | |
| MX2017001038A (es) | Variantes de proteina de unión al factor h y metodos de uso de estas. | |
| MX2020001287A (es) | Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos. |